ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Astellas Pharma and AstraZeneca in Prostatic Neoplasms

Their studies and programs in Prostatic Neoplasms, as the condition page counts them: each program at the phase its studies here reached, with their next primary completion here. Counts, not rankings.

Astellas Pharma×AstraZeneca×In Prostatic Neoplasms×

At a glance

Studies each sponsor leads that are filed under Prostatic Neoplasms, with the companies grouped under it. Every number opens the studies it counts.

Astellas PharmaAstraZeneca
studies in Prostatic Neoplasms5391
open to participants now515
phase 3 studies under way18
reach primary completion within a year28
programswith a study of their own here in two years, as the Prostatic Neoplasms page lists them410

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstellas PharmaAstraZeneca
Phase 1

Astellas Pharma: 1 of its 4 programs at phase 1

  1. fezolinetantphase 1
25%

AstraZeneca: 1 of its 10 programs at phase 1

  1. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
10%
Phase 2

Astellas Pharma: 2 of its 4 programs at phase 2

  1. ASP5541phase 2
  2. Prednisolonephase 2
50%
70%
Phase 300%

AstraZeneca: 2 of its 10 programs at phase 3

  1. saruparibphase 3
  2. Actinium-225phase 3
20%
Approved, new studies

Astellas Pharma: 1 of its 4 programs at approved, new studies

  1. enzalutamideapproved, new study
25%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Astellas Pharma2 readouts · 0 phase 3·····

Astellas Pharma, Apr ’27: 2 programs whose next study reaches primary completion

  1. enzalutamideapproved, new study · Apr 30 · NCT07783282
  2. fezolinetantphase 1 · Apr 30 · NCT07783282
······
AstraZeneca3 readouts · 0 phase 3

AstraZeneca, Nov ’26: 1 program whose next study reaches primary completion

  1. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729

AstraZeneca, Dec ’26: 1 program whose next study reaches primary completion

  1. zadavotide guraxetanphase 2 · Dec 23 · NCT06402331
····

AstraZeneca, May ’27: 1 program whose next study reaches primary completion

  1. saruparibphase 3 · May 28 · NCT04644068
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Astellas Pharma

New programs 0

None

Study stopped 0

None

Primary completion later 0

None

AstraZeneca

New programs 0

None

Study stopped 0

None

Primary completion later 0

None

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstellas PharmaAstraZeneca
ARenzalutamideruleAndrogen Receptor Degrader AZD9750rule
A target, or a pathogen for a vaccine, known for: Astellas Pharma 3 of 4 · AstraZeneca 9 of 10 programs (7 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • Within Prostatic Neoplasms: a program counts when one of its company’s studies of the last two years names Prostatic Neoplasms as its condition, as the condition page counts it; its phase and next readout are its studies’ here. Stage, biomarker and line of therapy are not read yet.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.